Healthcare Corporate Speak Misappropriates Terms Economics And Value
In boardrooms across America, phrases like “the economics don’t work” imply the inability to make a profit, rather than an evaluation of resource allocation or societal value. In an age of corporate medicine , this kind of talk now pervades healthcare discussions. But this strips the word economics of its original meaning as the study of how to optimally allocate scarce resources to achieve population-level goals such as better patient outcomes.
Almost 100 years ago, Lionel Robbins defined economics as the “science which studies human behavior as a relationship between ends and scarce means which have alternative uses.” In this context, economists examine the distribution of resources under the inevitable conditions of scarcity, focusing on how society can best produce, distribute and consume goods to optimize overall human well-being.
But the way the term economics is being co-opted today has little to do with social welfare. In everyday parlance it has turned into a corporate finance concept that mostly depicts profit extraction and sometimes even what is called rent-seeking. This occurs when companies attempt to increase their financial gain without creating any new wealth.
Undoubtedly, health economics partly reflects profit-seeking behavior by firms. But economists generally look further than that, at concepts such as opportunity costs and whether assumptions underlying competitive markets hold up. The former examines the value of the health benefits, services and technologies or life-years forgone when finite resources such as money, hospital beds, physician and staff time go towards one medical intervention instead of the next-best alternative.
At the same time, economists assess transactions in healthcare settings in light of possible violations of core assumptions that underlie properly functioning markets. These include asymmetric information between patients and doctors as well as buyers and sellers of healthcare products, relative low price sensitivity regarding services and technologies, considerable barriers to market entry, lack of transparency around pricing and the ubiquitous existence of monopolies and oligopolies.
Adopting corporate language presupposes an efficient market, which masks the reality that profit maximizing behavior in healthcare often relies on exploiting infringements of competitive market assumptions.
Some analyses evaluate key stakeholders such as pharmacy benefit managers from a health economics perspective. PBMs act as intermediaries between health insurers or employers, drug manufacturers, pharmacies and patients, managing prescription drug benefits, pricing and reimbursement. Others use corporate language — “ economics of PBMs " — while exploring conventional areas of health economics research such as probing for possible violations of market assumptions.
Nevertheless, the majority of analyses , testimonies and overviews tend to focus their “economics” discussions on ways that key players in the market such as PBMs can make money. When PBMs engage in “spread pricing” it’s then seen as part and parcel of PBM “economics .” Here, the PBM reimburses a pharmacy at a lower rate for a prescription purchased by a patient than what the PBM bills the patient’s employer or insurance plan.
The misappropriation of words extends beyond the term economics to include “value.” What does it imply when healthcare stakeholders create value? As a health economist, my understanding of the concept is that it’s a measure of benefit (patient outcomes) that a good or service provides. It can be generated by creating novel or improved products or lowering costs.
But in the healthcare business literature, value isn’t necessarily consistent with improving outcomes for patients. Rather, it can be viewed as finding different methods to monetize in the marketplace, whether this benefits patients or not. Corporate metrics for “value capture” may include bolstering profit margins, maximizing stock prices and securing market leverage through control of the distribution channels for goods and services. In other words, independent of whether clinical outcomes improve for patients, the business models that “create value” identify what’s monetizable.
So, for instance, if pharmaceutical manufacturers establish patent thickets, they can layer dozens or even hundreds of overlapping secondary patents onto an existing drug. This is often done to block cheaper generic competitors from entering the market. This confers value to the firms behaving this way. Commentators use phrases such as “lifecycle management” and “value creation” to describe such behavior. But it’s inconsistent with the economist’s understanding of the term.
Not all of the value talk is corporate driven. Value- or outcomes-based agreements have emerged as innovative ways to price and reimburse medical services and technologies. Value-based care is supposed to bridge commercialization and patient outcomes. It’s been a buzzword for decades. Arrangements based on value link some or all payments to measures of quality, outcomes, utilization or total cost of care. However, the proportion of care that is subject to value-based agreements is still relatively small.
Some of the consulting work I’ve been doing over the years involves assessment of revenues, margins and asset management. Needless to say, this isn’t health economics. But clients will often ask me about the “economics” related to a policy shift. Essentially, they want to know what kind of an impact changes in government or company policies will have on revenues, margins and asset management, and if there’s a corporate strategy that could effectively maintain “ value creation ” for the company or industry as a whole. This linguistic colonization of economics implies I must substitute financial accounting metrics for the concepts I was trained to deal with.